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SUMMARY 
The article comments on the recent systematic review and meta-analysis of dietary 
interventions for Crohn’s disease and ulcerative colitis. We discuss the pitfalls of current data 
and emphasize the importance of further research into diets and inflammatory bowel diseases. 
 
ABSTRACT 
There is vigorous interest among patients, caregivers, clinicians, and scientists to discover 
useful dietary interventions for inflammatory bowel diseases (IBD). Through the Cochrane 
Collaboration, we recently performed a systematic review and meta-analysis of dietary 
interventions for the induction or maintenance of remission in Crohn’s disease (CD) and 
ulcerative colitis (UC) to assess the latest state of research. The current quality of evidence was 
formally graded to be low or very low for various methodological reasons, such as small sample 
sizes, heterogeneity among studies, and incomplete reporting. There are nonetheless emerging 
observational studies that progressively advance our knowledge and provide hope for a role of 
diet among traditional therapies to improve inflammation and symptoms. Further investments 
and concerted efforts in research are needed to significantly move the needle in identifying 
effective dietary therapies for IBD.  
INTRODUCTION 
The hypothesis that pathogenesis of inflammatory bowel diseases (IBD) is strongly influenced 
by non-genetic (environmental) factors has fueled intense interest in identifying potentially 
modifiable factors for the prevention and treatment of IBD. Since one of the several pillars of this 
hypothesis is dysbiotic alterations in the gut microbiome, research efforts have explored diverse 
microbiome manipulation approaches, such as the use of prebiotics,1 probiotics,2-5 fecal 
microbiota transplantation,6 and diet as potential therapeutic strategies. The premise of these 
approaches presumes that reconfiguration of the microbiome toward a more “eubiotic” or less 
pro-inflammatory profile would lead to a reduction of intestinal inflammation. The premise of 
dietary manipulation takes a step further by hypothesizing that the reduced exposure to pro-
inflammatory antigens (e.g., additives, emulsifiers, omega-6 fatty acids) and/or addition of anti-
inflammatory constituents (e.g., omega-3 fatty acids, curcumin) in consumed foods would tip the 
balance toward a lower inflammatory profile. The feasibility of dietary therapies to influence 
intestinal inflammation is illustrated by the efficacy of exclusive enteral nutrition (EN) to induce 
remission in Crohn’s disease (CD), where society guidelines even recommend the use of 
exclusive EN as a steroid-sparing first-line therapy in children with active CD.7-10 Paradoxically, 
exclusive EN initially exacerbates dysbiosis by narrowing gut bacterial diversity and reducing 
gut concentrations of presumably protective bacteria, although dysbiosis eventually improves as 
inflammation resolves.11,12 These observations suggest that the mechanisms of dietary 
therapies’ benefits may include other factors in addition to the microbiome. Moreover, they 
reflect the complex interactions between diet and microbes, whereby bacterial diversity alone 
may be too simple of a marker of “microbial health”. 
There is currently vigorous interest among patients, caregivers, clinicians, and scientists 
to discover useful dietary interventions to either serve as primary or adjunctive therapy to 
optimize treatment response to traditional immunosuppressive agents. There is a dizzying array 
of anecdotes, conjectures, and misinformation about effective diets for IBD circulating on the 
Internet. Many of the recommendations extrapolate concepts from other gastrointestinal 
disorders, such as irritable bowel syndrome, but are generally unproven to reduce 
inflammation.13 The patients’ need to search and share dietary guidance within the online 
community is understandable, although there is an equally great need to address knowledge 
gaps and to differentiate fact from fiction. 
 
CURRENT STATE OF EVIDENCE 
A recent Cochrane systematic review and meta-analysis of dietary interventions for the 
induction or maintenance of remission in CD or ulcerative colitis (UC)14 has been published. All 
randomized controlled trials (RCTs) of dietary interventions for IBD through January 2019 were 
carefully reviewed, among which 18 RCTs with 1878 participants met criteria for quantitative 
and qualitative analyses. A description of the diets studied is available in the review.13 
For, CD, there were 6 studies evaluating 5 diet variants for the induction of remission. A 
highly restricted organic diet (relative risk [RR] 1.00; 95% confidence interval [CI] 0.39 – 2.53; 1 
study with 18 participants) and diets defined by a reduction in refined carbohydrates (RR 7.20; 
95% CI 0.53 – 97.83; 1 study with 7 participants), microparticles (RR 3.13; 95% CI 0.22 – 43.84; 
2 studies with 103 participants; I2 = 73%), or calcium (RR 1.24; 95% CI 0.67 – 2.29; 1 study with 
83 participants) did not confer added benefit over generic control diets for the achievement of 
clinical remission. On the other hand, a symptom-guided elimination diet was superior to 
“conventional nutritional advice” for achieving clinical remission in mild CD (RR 20.0; 95% CI 
1.27 – 315.40; 1 study with 51 participants). Only the study using a highly restricted organic diet 
evaluated inflammatory activity as an outcome and found no difference in serologic or 
endoscopic markers. For the maintenance of remission, there were 7 studies that evaluated 4 
types of exclusion diets. Diets with low refined carbohydrates (RR 1.04; 95% CI 0.87 – 1.25; 3 
studies with 567 participants; I2 = 35%), symptom-provoking foods (RR 0.53; 95% CI 0.28 – 
1.01; 2 studies with 98 participants; I2 = 54%), red or processed meats (RR 1.03; 95% CI 0.85 – 
1.26; 1 study with 214 participants), or a combination of the above (RR 0.11; 95% CI 0.01 – 
1.76; 1 study with 54 participants) were not superior than generic control diets for reducing 
clinical relapse. Other than two studies that measured C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR) concentrations, there were no outcomes of inflammatory disease 
activity. 
For UC, one study evaluated the symptoms-guided diet for the induction of remission 
and found no benefit over an unaltered diet for induction of remission (RR 8.25; 95% CI 0.50 – 
136.33; 21 participants). There was no clear endoscopic or histologic improvement either. Four 
studies evaluated 3 diets for the maintenance of remission. There was no difference in clinical 
relapse rates when comparing an anti-inflammatory diet (RR 1.25; 95% CI 0.42 – 3.70; 1 study 
with 28 participants), carrageenan-free diet (RR 0.50; 95% CI 0.15 – 1.64; 1 study with 15 
participants), or milk-free diet (RR 0.83; 95% CI 0.60 – 1.15; 2 studies with 77 participants; I2 = 
0%) with generic control diets. 
The certainty of evidence for each of these evaluated outcomes were formally graded as 
being low or very low, primarily due to small sample sizes, heterogeneity in the methods, and 
incomplete reporting on clinical trial quality measures (e.g., how blinding and analyses were 
performed). This currently would mean that there are no actionable dietary recommendations 
based on the available evidence. However, the likelihood is that these findings will change with 
more research. Notably, this is not the same as demonstrating lack of efficacy in any of the 
individual studies, rather, that the analyses demonstrate no definite conclusions can be reached 
based on the available evidence to date. It is worth noting that the well-established methods to 
judge bias, quality and certainty, these do not consider the quality of reporting of the intervention 
itself. This is not of real significance in studies of medications, but in the context of diet, the 
detail of the diet is vital as the application may vary greatly for similarly named diets and “300 
mg” of diet cannot be prescribed. 
While this systematic review used stringent criteria to formally assess the state of current 
RCT data for dietary interventions to treat IBD, non-randomized observational studies represent 
emerging sources of information that can potentially provide further insight into other diet 
candidates that need further exploration. Similar to the diets studied in published RCTs, variants 
of exclusion diets have been popular, such as the Specific Carbohydrate Diet (SCD),15 gluten-
free diet, and Crohn’s Disease Exclusion Diet (CDED).16 Early observational evidence has 
shown the SCD and CDED to potentially be helpful for inducing remission in CD.17-19 An 
extension to the theme of exclusion diets are those that incorporate nutrients with putative anti-
inflammatory or immunomodulatory properties; prototypes of such diets include the anti-
inflammatory diet and Mediterranean diet.20,21 These diets limit the consumption of refined 
carbohydrates and saturated fats, while leveraging potentially beneficial phytonutrients in fruits 
and vegetables, as well as oils (e.g., olive oil, fish oil) rich in omega-3 polyunsaturated fats. 
Given the established benefit of EN for induction of remission in CD, other diets (e.g., CD-
TREAT) attempt to recapitulate the microbiome effects of of EN,22 or combine them with partial 
EN.16 
While some of these observational studies show the potential of several diets for the 
treatment of IBD, there is a strong caveat about prematurely attributing efficacy using low-
quality evidence. For instance, a pilot RCT in 20 patients showed a significant difference in the 
change and resulting CDAI after 4 months, when comparing those who received the low 
microparticle diet versus a control diet.23 There was also an impressive difference of 70% 
versus 0% achieving clinical remission, respectively. However, when the investigators launched 
a similar follow-up trial with a more robust sample size of 83 participants, they found no 
difference between the low versus normal microparticle diets.24 This example illustrates the 
caution in overinterpreting small studies. Nonetheless, these studies serve a critical role for 
informing subsequent higher quality investigation, such as the CDED, PRODUCE 
(NCT03301311), and DINE-CD (NCT03058679) trials. After our systematic review, an RCT was 
published evaluating the efficacy of CDED coupled with partial EN for the induction of remission 
in 78 children with mild-to-moderate CD.16 Participants were initially randomized to either 
receive exclusive EN or 50% CDED (50% partial EN). There was no difference in 6-week 
clinical response between the groups, suggesting similarity in efficacy. Participants in the 
exclusive EN group thereafter transitioned to 75% unrestricted diet (25% partial EN), while 
those in the CDED group transitioned to 75% CDED (25% partial EN). By week 12, participants 
receiving CDED had greater sustained remission than those following an unrestricted diet. The 
other ongoing trials  were designed to rigorously compare the effectiveness of the SCD with a 
modified SCD (PRODUCE) or a Mediterranean-style diet (DINE-CD) for the induction of 
remission in IBD. 
 
CHALLENGES WITH RESEARCH 
The primary limitations with the current evidence on dietary interventions in IBD are their 
methodological design and execution. The sample sizes of available RCTs have been 
exceedingly low with a median among the studies of 38 participants. While it is possible that 
some of the diets may be effective for the induction or maintenance of remission, the trials’ 
inability to demonstrate significant benefit could realistically stem from having inadequate power 
to detect a difference between the treatment and control diets. Furthermore, heterogeneity in 
baseline disease activity, lack of clarity on what diets were consumed prior to enrollment, and 
the presence of other potential confounders would have a stronger influence on bias in small 
studies despite use of randomization to “homogenize” treatment populations. 
There was great heterogeneity among dietary interventions studied, generally leaving 
only 1 or 2 trials per type of diet and diminishing the benefit of meta-analyses for overcoming 
small sample sizes by aggregating similar studies in an effort to generate specific guidance for 
clinicians and patients. This heterogeneity of interventions reflects the disparities in individual 
research efforts, transient research interest in each diet, and our current lack of understanding 
or agreement on what constitutes the ideal diet. We do not yet understand what constitutes an 
“optimal dose” of anti-inflammatory nutrients. Linked to this is the assumption that the 
description of similar diets may not actually accurately match what the patient is actually given 
or indeed complies with.  
The methods of dietary intervention, including assessment and assurance that the right 
foods within the designated diets were selected or even consumed (compliance) are unclear. 
These concerns are highly prevalent in dietary intervention studies where, unless the 
investigators provide the meals to participants, maintaining them within the strict parameters of 
what define the dietary intervention can be practically very challenging.  
The outcomes selected for the available RCTs have predominantly focused on symptom 
scores to define clinical remission. There is a general lack of objective markers of inflammatory 
activity, such as endoscopic or histologic outcomes, or dysbiosis. Symptoms can improve with 
dietary modification, particularly learned avoidance of symptom-provoking foods; however, the 
impact of these modifications on inflammation, a central mechanism that drives symptoms and 
the progression of disease, would still be unknown. The Crohn’s Disease Activity Index (CDAI) 
used in many studies is strongly dependent on reported symptoms, so it is not surprising that 
participants who avoided symptoms-provoking foods would experience fewer symptoms.  
The risk of bias assessment showed that many of the trials had a high or unclear risk of 
bias. The high risk of bias predominantly involved inadequate blinding of participants and 
personnel, although this may be a general limitation of dietary interventions, as the types, 
tastes, and textures of food would be difficult to homogenize across treatment arms. The 
recently devised update to the Cochrane risk of bias tool may allow such elements to not be 
rated as high risk in the future. However, much of the unclear risk of bias stemmed from 
inadequate reporting on how randomization was performed. This oversight could have been 
easily circumvented and given their key role in ensuring adequate trial design, this is a 
significant issue with the evidence base. 
In an attempt to overcome these methodologic challenges, the DINE-CD trial has a 
robust sample size target of 194 participants, provides prepared meals to minimize 
heterogeneity of consumed foods, and employs fecal calprotectin as a surrogate marker of 
inflammation in addition to reported symptoms. Nonetheless, despite the rigor in its study 
design, the interventions are not blinded and there are no endoscopic or histologic data. These 
limitations were not due to oversight, but illustrate the added challenges of balancing cost and 
practicality when designing high-quality studies, practicality, and the need for a high-quality 
study. 
 
CALL TO THE ROUND [DINING] TABLE 
The major gastroenterological societies are relatively silent on the role of dietary therapies in 
IBD, except for recommendations on the use of exclusive EN for CD (Table 1). The current lack 
of evidence on dietary therapies for IBD does not necessarily signify that they have no role in 
helping control inflammation. Given the diet’s and gut microbiome’s known effects in altering 
inflammation at the molecular level, the potential to eventually identify diets that macroscopically 
affect inflammation endoscopically and histologically is strong. We just do not yet know which 
diets and in what context they would be helpful, such as in prevention or treatment of IBD. The 
interactions between food and biology are immensely complex; while EN is recommended for 
the induction of remission in children with active CD, it is not efficacious for UC. This disparity 
demonstrates that dietary alteration of pro-inflammatory and anti-inflammatory substances does 
not alone explain nutritional therapies’ effect on inflammation. Furthermore, studies with children 
on EN demonstrate changes in the microbiota that may be considered further than normal 
despite the clinical improvements seen. These findings suggest that dietary interventions have 
complex and multiple unexpected effects that are yet to be fully explored. There are also very 
likely patient-specific factors that influence the potential efficacy of dietary therapy. It is also still 
unclear whether diet may serve as a primary or adjunctive therapy. Would it be an aid for 
improving overall response to a backbone of pharmacologic immunosuppression or a method to 
permit partial therapy de-escalation? The position of dietary therapy in the overall treatment 
algorithm and the clinical and/or genetic factors that determine in whom these would be 
appropriate (personalized nutrition) have yet to be defined. As many of the dietary studies have 
been done in children, the translatability of these findings to the adult population, or vice versa, 
is also unknown. 
This is therefore a call to arms – or, to the dining table – that a concerted effort to 
advance research on dietary therapies in IBD is needed. The dearth of RCTs, most dating back 
many years and some published only as abstracts, reflects the relative lack of attention on this 
area of research and the challenges faced by researchers to engage in well-designed trials. 
There is a need for interest and investment in these costly endeavors. There is a need to push 
forward with research programs on particular diets to progressively accumulate data. 
Unfortunately, the majority of the RCTs and diets in the systematic review never moved beyond 
the first small study. Even the symptoms-guided diet that was reportedly effective at improving 
symptoms in CD was never published. With many small studies with heterogeneous diets, the 
data needed to demonstrate dietary efficacy – if true – would not be expected to be generated. 
The methodologic challenges with many of the available dietary intervention studies also need 
to be addressed and improved. Lewis et al provide valuable guidance on key considerations 
when designing such trials.25  
The patient community participates in research trials to help build evidence that would 
hopefully benefit them and their peers in the future. Funding agencies and philanthropists 
contribute resources in hopes of helping the discovery of important and innovative therapies. 
Unlike drug development trials, lack of funding opportunities presents a major challenge unique 
to diet studies. In the absence of such funding, the state of nutrition research in IBD will 
continue to progress at a glacial pace. It behooves the research community to make use of 
these investments to build on the growing foundation of knowledge and eventually generate 
high-quality evidence to show whether and what diets may be used to treat IBD or not. 
Ensuring that such research is performed in a manner that will increase the likelihood of 
impact is vital. We believe that international societies need to coordinate a strategy based on 
current evidence of all forms. Key candidate therapies should be agreed on and a public unified 
call made to encourage research focused in these areas. These discussions must include 
patient advocate societies and charities, as patient views on the tolerability, cost, and interest in 
diets will be vital in gaining momentum for investigation. So, we end with a call not just to the 
dining table, but to the virtual round table to bring forth the much needed highly relevant 
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